Andarix Pharmaceuticals has appointed new clinical oncology experts to its clinical advisory board to help with the development of its lead drug candidate, P2045. The drug is a treatment for lung and other cancers and is based on a radiolabeled somatostatin peptide analogue.

Full Story:
PR Web

Related Summaries